Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses

BACKGROUND: There are no validated biomarkers that can aid clinicians in selecting who would best benefit from anticytotoxic T lymphocyte-associated antigen 4 monotherapy versus combination checkpoint blockade in patients with advanced melanoma who have progressive disease after programmed death 1 (...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedman, Claire F, Spencer, Christine, Cabanski, Christopher R, Panageas, Katherine S, Wells, Daniel K, Ribas, Antoni, Tawbi, Hussein, Tsai, Katy, Postow, Michael, Shoushtari, Alexander, Chapman, Paul, Karakunnel, Joyson, Bucktrout, Samantha, Gherardini, Pier, Hollmann, Travis J, Chen, Richard O, Callahan, Margaret, LaVallee, Theresa, Ibrahim, Ramy, Wolchok, Jedd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788323/
https://www.ncbi.nlm.nih.gov/pubmed/35074903
http://dx.doi.org/10.1136/jitc-2021-003853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8788323/
https://www.ncbi.nlm.nih.gov/pubmed/35074903
http://dx.doi.org/10.1136/jitc-2021-003853

Ejemplares similares